Sugi Predict

Sugi Predict / Compounds / Erizepine

Erizepine

Erizepine

SCHEMBL2109749

CN1CCC2=C(CC1)c1ccccc1N(C)c1ccccc12

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 4/20 0.56
▸ DRD3 P35462 4/20 0.56
▸ CHRM2 P08172 3/20 0.56
▸ HTR1A P08908 3/20 0.56
▸ ADRA2A P08913 3/20 0.56
▸ CHRM1 P11229 3/20 0.56
▸ SLC6A2 P23975 3/20 0.56
▸ SLC6A4 P31645 3/20 0.56
▸ ADRA1A P35348 3/20 0.56
▸ OPRM1 P35372 3/20 0.56
▸ SLC6A3 Q01959 3/20 0.56
▸ KCNH2 Q12809 3/20 0.56
▸ SETD7 Q8WTS6 6/20 0.50
▸ DRD2 P14416 3/20 0.45
▸ MAOA P21397 2/20 0.45
▸ MAOB P27338 2/20 0.45
▸ DRD4 P21917 2/20 0.45
▸ DRD5 P21918 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ ADRA2C P18825 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Erizepine SCHEMBL30305570 1.00 DRD1 (0.56) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10727679 0.82 DRD1 (0.50) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10728179 0.78 DRD1 (0.86) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL25635330 0.75 TTR (0.58) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10734779 0.74 DRD3 (0.69) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10734259 0.74 DRD1 (0.54) DRD1DRD3CHRM2HTR1AADRA2A
Maroxepin SCHEMBL2108201 0.74 SETD7 (0.69) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL11652592 0.74 TTR (0.46) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL31628974 0.73 ACHE (0.64) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL2604394 0.73 TTR (0.56) DRD1DRD3CHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-11931366-B2 Compositions and methods of use thereof for treatment of proteinopathies WASHINGTON UNIVERSITY (US) 2024-03-19 — — US disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-20210228591-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES WASHINGTON UNIVERSITY 2021-07-29 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
WO-2019204764-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES WASHINGTON UNIVERSITY (US) 2019-10-24 — — WO disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 — — US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed
US-4707476-A TRANQUILIZERS CIBA-GEIGY CORPORATION (US) 1987-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931366-B2 Compositions and methods of use thereof for treatment of proteinopathies SERPINA2, FABP1, TTR DRD1 4499/4885DRD3 4620/4885CHRM2 4248/4885
US-20210228591-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES SERPINA2, FABP1, TTR DRD1 4499/4885DRD3 4620/4885CHRM2 4248/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 DRD1 4663/4885DRD3 4723/4885CHRM2 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.